Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy

Background: The use of rivaroxaban in clinical practice often deviates from manufacturer prescribing information. No studies have demonstrated an association between this practice and improved outcomes. Methods: We used the RIETE registry to assess the clinical characteristics of patients with pulmo...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Pierpaolo Di Micco, Vladimir Rosa Salazar, Carmen Fernandez Capitan, Francesco Dentali, Covadonga Gomez Cuervo, José Luis Fernández Reyes, Jose Antonio Porras, Angeles Fidalgo, Elvira Grandone, Manuel Lopez Meseguer, Manuel Monreal, the RIETE Investigators
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2022-07-01
Цуврал:	Life
Нөхцлүүд:	oral anticoagulants DOACs rivaroxaban venpus thromboembolism RIETE
Онлайн хандалт:	https://www.mdpi.com/2075-1729/12/8/1128
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!